Effects of rhCC10 as a Post-Treatment in Mice Challenged with Phosgene
Abstract
In this study we evaluated the therapeutic efficacy of a post-exposure administration of rhCC10 (Claragen, Inc., Rockville, MD) against a toxic concentration of phosgene. rhCC10 0 is described as a 1 10kDa Clara Cell protein, an anti-inflammatory lung protein that is present on all mammalian mucosal surfaces. It protects against infection and environmental pollutants but apparently not against phosgene, which has a substantial effect in bronchioles and permeability in the deep alveolar lung. Supplementation with rhCC10 did not increase survival of animals exposed to phosgene compared with those treated with saline alone. In addition, the results of the bioassays show no significant differences between saline and the rhCC10 doses; therefore, there has not been any determination of rhCC10 as a beneficial post-exposure therapy for phosgene.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 2005
- Accession Number
- ADA443098
Entities
People
- A. M. Sciuto
- R. B. Lee
- T. S. Moran
- Z. A. Hess
Organizations
- United States Army Medical Research Institute of Chemical Defense